Revolution Medicines closed a flexible funding agreement with Royalty Pharma for up to $2 billion to accelerate late-stage development and commercialization of its RAS(ON) inhibitors, including daraxonrasib. This capital infusion supports Revolution’s strategy to internally lead global development and marketing, marking a significant milestone for targeted therapies addressing RAS-driven cancers.